Objective: To explore the pivotal points of pharmaceutical care for rituximab in the treatment of children with steroiddependent nephrotic syndrome. Methods: Taking a child with steroid-dependent nephrotic syndrome treated with rituximab as an example

clinical pharmacists provided comprehensive pharmaceutical care throughout the use of rituximab. Results: Clinical pharmacists provided pharmaceutical recommendations regarding the dosage of rituximab

prevention of adverse drug reactions

and prevention of Pneumocystis jirovecii infection

which improved the safety and efficacy of children’s medication. Conclusion: As members of the clinical treatment team

clinical pharmacists play an active role in individualized drug therapy in clinical practice.